| Alzheimer's Disease
Kisunla vs Namzaric
Side-by-side clinical, coverage, and cost comparison for alzheimer's disease.Deep comparison between: Kisunla vs Namzaric with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsNamzaric has a higher rate of injection site reactions vs Kisunla based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Namzaric but not Kisunla, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Kisunla
Namzaric
At A Glance
IV infusion
Every 4 weeks
Anti-amyloid beta mAb
Oral
Once daily
NMDA antagonist / AChE inhibitor
Indications
- Alzheimer's Disease
- Alzheimer's Disease
Dosing
Alzheimer's Disease Escalating IV infusion over approximately 30 minutes every 4 weeks: 350 mg (infusion 1), 700 mg (infusion 2), 1,050 mg (infusion 3), 1,400 mg (infusion 4 and beyond); consider stopping based on reduction of amyloid plaques to minimal levels on amyloid PET imaging.
Alzheimer's Disease Recommended starting dose 7 mg/10 mg once daily in the evening; increase in 7 mg increments at minimum weekly intervals to maintenance dose of 28 mg/10 mg once daily in the evening.
Alzheimer's Disease, Severe Renal Impairment Recommended maintenance dose is 14 mg/10 mg once daily in the evening for patients with severe renal impairment (creatinine clearance 5-29 mL/min).
Contraindications
- Known serious hypersensitivity to donanemab-azbt or any excipient, including anaphylaxis
- Known hypersensitivity to memantine hydrochloride, donepezil hydrochloride, piperidine derivatives, or any excipient in the formulation
Adverse Reactions
Most common (>=5%) ARIA-H microhemorrhage, ARIA-E, ARIA-H superficial siderosis, headache, infusion-related reaction
Serious Hypersensitivity reactions (including anaphylaxis), intestinal obstruction, intestinal perforation, ARIA-E, ARIA-H
Most common (>=5%) Headache, diarrhea, dizziness (memantine); diarrhea, anorexia, vomiting, nausea, ecchymosis (donepezil, severe AD); insomnia, muscle cramp, fatigue (donepezil, mild to moderate AD).
Serious Cardiovascular conditions, peptic ulcer disease, gastrointestinal bleeding, nausea and vomiting, genitourinary conditions, seizures, pulmonary conditions.
Postmarketing Memantine: acute renal failure, agranulocytosis, congestive cardiac failure, hepatitis, leukopenia, pancreatitis, pancytopenia, Stevens-Johnson syndrome, suicidal ideation, thrombocytopenia, thrombotic thrombocytopenic purpura. Donepezil: abdominal pain, agitation, cholecystitis, confusion, convulsions, hallucinations, heart block, hemolytic anemia, hepatitis, hyponatremia, neuroleptic malignant syndrome, pancreatitis, rash.
Pharmacology
Donanemab-azbt is a humanized IgG1 monoclonal antibody directed against insoluble N-truncated pyroglutamate amyloid beta; it reduces amyloid beta plaques in the brain, a defining pathophysiological feature of Alzheimer's disease.
NAMZARIC combines memantine, a low to moderate affinity uncompetitive NMDA receptor antagonist that blocks excessive glutamatergic activity, and donepezil, a reversible acetylcholinesterase inhibitor that increases central cholinergic transmission by inhibiting hydrolysis of acetylcholine; each component addresses a distinct postulated pathophysiological mechanism in Alzheimer's disease.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Kisunla
- Covered on 5 commercial plans
- PA (1/12) · Step Therapy (0/12) · Qty limit (0/12)
Namzaric
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (1/12) · Qty limit (9/12)
UnitedHealthcare
Kisunla
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Namzaric
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Kisunla
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (0/3)
Namzaric
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (1/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$0/fillfill
Kisunla Savings Card ProgramCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
No savings programs available for Namzaric.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
KisunlaView full Kisunla profile
NamzaricView full Namzaric profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.